Biotech · Private company
ONL Therapeutics
Track this companyFree. Adds ONL Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- Avacincaptad Pegol intravitreal solutionPhase 2 · Geographic Atrophy (GA)ClinicalTrials.gov · fetched Nov 12, 2026
- ONL1204 Ophthalmic SolutionPhase 2 · Rhegmatogenous Retinal Detachment - Macula OffClinicalTrials.gov · fetched Nov 12, 2026
- ONL1204 Opthalmic solutionPhase 2 · Geographic Atrophy (GA)ClinicalTrials.gov · fetched Nov 12, 2026
- ShamPhase 2 · Geographic Atrophy (GA)ClinicalTrials.gov · fetched Nov 12, 2026
- Sham treatmentPhase 2 · Rhegmatogenous Retinal Detachment - Macula OffClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMDPHASE2 · RECRUITING · started Oct 28, 2025ClinicalTrials.gov NCT06659445 · fetched Nov 12, 2026
- A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal DetachmentPHASE2 · COMPLETED · started Apr 4, 2023ClinicalTrials.gov NCT05730218 · fetched Nov 12, 2026